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ABSTRACT 
 
 
DESIGN, SYNTHESIS AND CHARACTERIZATION OF ACTIVATABLE 
PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY 
 
Fatma Pir Çakmak 
M.S. in Department of Chemistry 
Supervisor: Prof. Dr. Engin U. Akkaya 
July, 2012 
 
Search for new noninvasive methods for diseases has been significant question 
for years. Therapeutic properties of light are combined with proper chromophore 
in order to create fundamentals of photodynamic therapy which is a new 
treatment modality for cancer and other various non-oncological diseases. The 
method relies on the activation of photosensitizer by using light of certain 
wavelength and generation of cytotoxic singlet oxygen species in response. 
Reactive oxygen species kill the targeted tissue within smaller effective diameter 
through apoptosis/ necrosis mechanism. Through this method, new PDT agents 
can be proposed and their properties can be tuned by manipulation of other 
photophysical processes. In this thesis, synthesis, characterization novel water 
soluble, near IR absorbing Bodipy photosensitizer will be discussed. As opposed 
to other photosensitizers in literature, this photosensitizer is rationally designed 
to have singlet oxygen generation capability only in cancer tissue as a result of 
glutathione triggered activation.  
Keywords: Bodipy, photodynamic therapy, Glutathione, water soluble 
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ÖZET 
 
 
 
FOTODİNAMİK TERAPİ İÇİN IŞIK DUYARLAŞTIRICILARIN 
SENTEZİ VE KARAKTERİZASYONU 
 
Fatma Pir Çakmak 
Yüksek Lisans, Kimya Bölümü 
Tez Yöneticisi: Prof. Dr. Engin U. Akkaya 
Temmuz, 2012 
 
 Hastalıklar için non-invaziv yöntemler geliştirmek araştırmaların önemli 
bir sorusu olarak yıllardır ele alınmaktadır. Işığın terapatik etkileri ve uygun 
kromofor kullanımı harmanlanarak kanser ve diğer hastalıklar için kullanılan 
fotodinamik terapinin temelleri oluşturulmaktadır. Method uygun dalga boyunda 
ışık kullanımı ile ışık duyarlaştırıcılarının aktivasyonu sonucu sitotoksik singlet 
oksijen üretimine dayanmaktadır. Reaktif oksijen molekülleri etkili küçük bir 
yarıçapta apoptozis ve nekroz mekanizmaları ile hedeflenen dokuyu 
öldürmektedir. Diğer fotofiziksel yöntemlerin kullanımı ile yeni fotodinamik 
terapi ajanları tasarlanıp özellikleri tasarlanabilir. Bu tezde, orijinal suda 
çözünebilen, yakın kızıl ötesi soğuran Bodipy fotoduyarlaştırıcının sentezi ve 
karakterizasyonu tartışılacaktır. Bu fotoduyarlaştırıcı literatürdeki diğer 
fotoduyarlaştırıcıların aksine sadece kanserli bölgede glutatyon ile aktive olup 
reaktif oksijen üretme yeteneğine sahiptir.  
 
 
Anahtar Kelimeler: Bodipy, Fotodinamik terapi, Glutatyon, suda çözünür  
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CHAPTER 1 
INTRODUCTION 
 
1.1. Photodynamic Therapy 
 
Therapeutic effects of light
1,2
 have been known for thousands of years. 
Photodynamic therapy (PDT) is a new promising treatment method
3
 which was 
developed just in the last century. Unlike to other traditional cancer therapies, 
PDT gives damage to targeted tissue
4,5
 not surrounding normal cells. PDT 
depend on systemic localization of photosensitizers in targeted tissue and 
activation of the sensitizer
6
 by using red or near infrared (NIR) light which 
allow generation of singlet oxygen (
1
O2). Hence this strategy gives damages to 
cancer cells which exposed to light within therapeutic window (650-800 nm).  
Pronounced properties of PDT over conventional strategies help widely 
use of the method in clinical trials
7
. All current clinical PDT agents have ability 
to target specific tissue with different range of sensitivity. The method 
harnesses harmless components as light and photosensitizer turn into 
destructive elements toward tumor. The other crucial parameter is molecular 
oxygen for the method. Energy transfer from photosensitizer to molecular 
oxygen allows transformation of oxygen molecules to reactive singlet oxygen 
species. These reactive oxygen species has short life time and give its additional 
energy to surrounding tissue which causes cell death either with apoptosis or 
necrosis
8
. So far there are various photosensitizers
9
 reported for clinical 
treatments.  
Scientists are seeking for new improved version
6
 of the method in order 
to have more sensitive approach for diseases. Since clinical trials have begun, 
searching for answers also has progressed in the laboratory. Every step and 
enhancement has been highlighted in the area in view of the fact that cancer has 
2 
 
become the second cause of the death after heart related disorder in the world 
according to statistics.  
 
1.1.1 Photosensitizers 
Several compounds can be considered as appropriate PDT agents
10
 due to 
their ability to produce singlet oxygen nonetheless only a few of them could be 
used in clinical trial
7,11
 even less could be commercially available
12,13,14
. Most 
common photosensitizers
15
 have porphyrinoid structure. One of them is the first 
used hematoporphyrin derivative, Photofrin
16,17
 which has been approved in 
Europe, Canada, Japan and United States
4
 although it doesn’t carry optimal 
properties
18,19
 of a photosensitizer for PDT. The reasons
20
 for wide use of 
hematoporphyrin derivatives
21,22
 in first generation photosensitizer are wide 
knowledge of these compounds and their resemblance with natural porphyrins 
which can be found in living organism. 
For aiming ideal photosensitizers for PDT, there are many requirements 
should be kept in mind. Suitable photosensitizer agents for PDT should have 
ease of purification / synthesis
23
 for beginning. Another important factor is 
related with the wavelength of the light. The photosensitizers need to have 
maximum absorption in the region 600-800 nm which is optimum range
15,24
 for 
energy necessity and deep tissue penetration in addition to this; minimum 
absorption
25
should be in the region 400-600 nm in order to reduce skin 
photosensitivity. Dark toxicity and phototoxicity
20,11
 is one of the important 
drawbacks of the sensitizers which have been used in clinical trials. Also 
compounds which are going to be used as PDT agents need to be photostable 
towards photodegradation and other reactive oxygen species. Upon 
administration of the photosensitizer, it should be highly selective for malignant 
tissue
26
 instead of healthy tissues. Well characterized single compound
15
 is 
needed in order to have dependable examination of sensitizer in PDT 
mechanism. High quantum yields
20
 for phosphorescence and singlet oxygen 
generation can be added to our lists for designing new sensitizers. 
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Biocompatibility of the compounds determines its direct application. In order to 
increase biocompatibility, solubility
27,23
 carries important role for 
administration and distribution of the sensitizers in vivo applications. Although 
solubility is significant character of photosensitizers, there are many studies 
enable of hydrophobic PDT agents administration through improving of water 
soluble carriers
28,29,30
. Also these carriers can be characterized for additional 
selectivity by manipulating specific interactions.  
 
1.1.1.1 Porphyrin Related Photosensitizers 
Second generation PDT agents
24
 are designed after photofrin
31
 and they still 
depend on the diverse types of polypyrrole macrocycles. A range of them have 
begun to be used in phase I/ II and II/III clinical trials
15,32
 (Fig. 1).  m-
Tetrahydroxyphenyl chlorin
33,34
 (compound 1) also known as Temoporfin and 
Foscan has been used for treatment for the head and neck cancers in Europe. 
Although scientist obtained promising results for this compound, extended skin 
photosensitivity is reported as a negative aspect
35
. Compound 2 resembles more 
like the photofrin as hematoporphyrin derivatives
9
. Compound 3 belongs to 
porphyrin family and called protoporphyrin IX
36,37,38
 which is also precursor of 
5-aminolevulinic acid (ALA). Mono-L-aspartyl chlorine e6 (Npe6) is another 
second generation phosensitizer illustrated as compound 4 which has been used 
for lung cancer in phase I/ II trials
4, 39
. Palladium bacteriochlorin (Tookad)
40
 is 
an example of co-coordinated metal atoms within tetrapyrrole which is showed 
as compound 5 in Fig.1. Compound 6 has been used for clinical trials for breast 
cancer and other cutaneous tumors under the name of Verteporfin
41,42
. It is 
benzoporphyrin derivative monoacid ring A (BDP-MA) which is also used for 
age related molecular degeneration (AMD)
43
. All of the examples are at 
different phase of clinical trials. Although some of them show a few promising 
results
44,45
, there is many improvements needed for ideal photosensitizer. There 
are also many drawback related with these compound. One of them is toxicity 
4 
 
which has been observed during clinical trials. Studies also has important role 
in the improvement of new generation photosensitizers. With the help of the 
results obtaining from clinical trials, scientist could interpret them and  
Figure 1. PDT agents as second generation 
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demonstrate the significant characteristic of ideal photosensitizer. 
Understanding of the concept has gained new aspects with the help of the 
experience during the period of clinical trials. 
In Fig.1, we could find examples of the photosensitizer which is called 
second generation. There are also other photosensitizers which are also 
porphyrin related. Core modified porphyrin can be example of this class. These 
sensitizers have been tried to be improved during clinical trials. Some of them 
are far from being ideal PDT agents in order to have better treatment of cancer 
and other diseases. Since this thesis is more related to cancer, examples will be 
more associated to it. Various types of cancer types were used in these clinical 
trials as it can be seen through the examples
11
. 
 
1.1.1.2 Non- Porphyrin Related Photosensitizers 
Due to the several drawbacks of porphyrin related compounds, scientists 
have found alternatives. The major negative aspects are poor light absorption in 
near infra-red and long timed skin photosensitivity
15
. Although one of the 
important reasons is to choose porphyrin related compounds as photosensitizers 
is they are naturally occurring substance, there are many instances of natural 
non-porphyrin related compounds
46
. Considering the factors needed for ideal 
photosensitizers, there are many researches aiming to design optimum PDT 
agents.  
Compound 7 (in Fig.2) is an example of Psoralen derivatives
47
 which has 
been applied for thousands of years in Middle East and East for mostly skin 
disorders. Studies enlighten the structure-activity relation and synthetic 
pathways for different kinds of them. It is claimed that these compounds 
selective for cancer cells. Other important results propose these compounds 
result cross linking in DNA
48
. This characteristic can be deadly for especially in 
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the case of non-tumor tissues. Various types of Psoralen show different 
properties in PDT action. Clinical trials are continuing with these compounds.  
Compound 8 is an example of anthracyclines and called Doxorubicin
49
 
which has suitable light absorption properties and tumor selectivity. Even 
though this favorable properties of this compound, it has harmful effects on 
healthy tissues. Pharmacology of the substance has been cracked through the 
clinical trials. Lower dose of this compound could show better cytotoxic effect 
towards tumors when compared to other photosensitizers. Negative aspects of 
this compound for PDT need to be improved with the help of the knowledge 
which is gained during various researches.  
Merocyanine
50
 (Compound 9) is illustrated in Fig.2 as a model for 
cyanine dyes which is an early subject of PDT. They are known for their 
antibacterial property and straightforward synthesis. Their absorption is not in 
the optimum range but it can be modified through manipulating length of 
polymethine chains. However this arouses other problems as decrease in 
stability and solubility. Since PDT agents are designed for in vivo applications, 
all the properties of photosensitizer should be carefully considered. Also these 
dyes have been used in clinical trials in order to understand its characteristic 
better. Structure of this compound enables extensive design of different series
51
. 
On the other hand, low quantum yields of singlet oxygen generation are 
observed during trials as disadvantage. Heavy atom effect could be used to 
increase the quantum yield for singlet oxygen but other negative aspects of this 
compound need to be improved. 
With a more common name methylene blue
52
 as a derivative of 
phenothiazinium dyes is shown in Fig.2. as compound 10. It has been used 
extensively for clinical diagnosis and tumor marker although its use as 
photosensitizer is new when compared to others. Its performance has been 
diminished by malignant cells even though it gives damage to DNA during 
PDT action
53
. Other reason not to use of methylene blue for PDT action can be 
its dark toxicity. Different synthetic pathways are also available.  
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Figure 2. Non-porphyrin related PDT agents 
8 
 
Another popular dye is Rhodamine derivatives
54
 which are demonstrated 
as compound 11 in Fig.2. It has been known for its use for fluorescent probe. 
This dye shows high fluorescence quantum yields which enable to have 
increased singlet oxygen generation efficiency compared to others. However, 
dark toxicity of this compound and short wavelength absorption made 
Rhodamine far away from being ideal photosensitizer
55
.  
Triarylmethane derivative crystal violet is illustrated as compound 12 
which is recognized for its antimicrobial and antitumor properties
56
. It is also 
used for PDT action though it is hard to explore its singlet oxygen generation 
efficiency because of its structure. Low dark toxicity and absorption at proper 
wavelength can be listed as advantages of these compounds. Also clinical trials 
suggest that dye has high photoactivity against tumors. In addition its charge 
allow cell uptake
57
. 
Compound 13 is an example of acridines family
46
 as a simple compound 
called acridine. This group is widely studied heterocyclic compound. Its PDT 
effect has known for a century by now. Another characteristic of this compound 
is use of fluorescent probe. Although this knowledge, acridines compounds 
have been used in clinical trials less than expected.  Upon the photoirridation
58
, 
compound gives enhanced damage to DNA strands and there are many 
commercially available acridines in market. Phototoxicity and short wavelength 
absorption of these compounds can be listed its drawbacks. 
The last but not the least non-porphyrin related photosensitizer is called 
Bodipy
59
 and illustrated as compound 14. Although these compounds have been 
known for years, it has been studied for PDT just for last years. Ease of 
synthesis, ease of purification, good photostability, absorption in therapeutic 
window, high extinction coefficients and good quantum yields for singlet 
oxygen generation are the reasons for these compounds to use in PDT methods. 
Also many researchers have proposed its excellent photophysical 
characteristic
23
 which allow manipulation to meet the criteria of ideal PDT 
agents.  
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1.1.2 Photochemistry of Photodynamic Therapy 
Localization of the photosensitizer in targeted tumor tissue is 
administrated. Upon irridation, photosensitizer absorbs energy at determined 
proper wavelength, and get excited to upper energy level. Its energy is 
transferred to oxygen molecules which cause cell death in the end. 
Absorption of a photon by ground state photosensitizer (S0), allow 
excitation of molecules to its short lived excited singlet state (S1) by using 
conventional light sources. Singlet and triplet state lifetimes are differ from 
each other. Singlet lifetimes generally determined in nanoseconds whereas 
triplet lifetimes are defined in the range of microsecond to millisecond
60
.  
 
 
Figure 3. Perrin−Jablonski energy diagram for a PS molecule60 Copyright © 
2010, American Chemical Society. Adapted with permission 
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Other excited states may be possible
61
 for the substance depending of the nature 
of the photosensitizer and the wavelength of the light used in the experiment. 
Singlet excited state lifetime is very short to enable interaction between 
photosensitizer and oxygen molecules hence the damage caused by the 
molecules at this singlet excited state is insignificant. Due to its longer lifetime, 
triplet excited states (T1) are preferred for biological applications of 
photochemistry. At this point there are two options occur for photosensitizer: 
radiative or non-radiative paths.  
It can re-emit its energy via fluorescence route or it can go through 
intersystem crossing process. Also non-radiative decay can be possible for 
molecules in other cases in which molecule produce heat during the process. 
Rate constant demonstrated for fluorescence kf, for non-radiative decay knr and 
for intersystem crossing kısc in the Fig.3. Although there are studies showing 
that internal conversion in non radiative decay path can be manipulated for 
photosensitized tissue damage, the most important path for dispersing energy to 
surroundings more specifically to molecular oxygen is internal conversion since 
it favors to excited triplet state (T1). As it is mentioned, excited triplet state (T1) 
has longer lifetime allowing energy transfer probable. On the other hand 
transition from singlet state to triplet state is spin forbidden and vice versa 
which also is the reason longer lifetime of triplet state. Heavy atoms such as 
chlorine, iodine modifications to photosensitizer increase intersystem crossing 
rate leading enhanced photodynamic activity. In order to generate singlet 
oxygen species (
1
O2) from molecular oxygen (
3
O2), certain amount energy is 
needed in which determine the upper limit of wavelength of therapeutic 
window for photodynamic therapy. This energy which is 22 kcal mol
-1
 is very 
low. Furthermore there is other possibility as phosphorescence rate illustrated 
kp for excited triplet state other than transferring its energy to surroundings. 
Other more complex photophysical incidents can take place for molecules
3,60
. 
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Figure 4. Photochemical Reactions during PDT action
62
 Copyright © 2008, 
Springer-Verlag London Limited Adapted with permission 
Another question arouses about possible pathways for generation of reactive 
singlet oxygen. It can be divided into two groups as Type I and Type II
62
 (Fig. 
4). Type I procedure includes hydrogen-atom abstraction or electron transfer 
between excited photosensitizer and substance which produce free radicals. 
These radicals can interact with oxygen molecule in order to generate reactive 
oxygen species as superoxide radical which is not sufficient reactive to give 
damage. These superoxide radicals instead generate hydrogen peroxide (H2O2) 
which can give damage to tissues through various pathways
63,64
. In Type II 
mechanism, energy transfer occurs from triplet excited state of photosensitizer 
to molecular oxygen directly. This energy transfer lead reactive singlet oxygen 
generation which is known for a variety of interaction with biological 
substances in response causing cell death through oxidative stress. Oxygen and 
photosensitizer concentration are just examples of the parameters which define 
the mechanism of generation reactive oxygen species
64,65
.  
Oxygen has destructive role independent of the reactions types. Oxygen 
level in tissue is needed to meet the required amount for tissue damage. Also 
there are studies confirming this hypothesis. In its ground state, oxygen has two 
unpaired which is the reason of its triplet state. Through energy transfer, these 
electrons are pair up and become singlet state which leads to destruction of 
12 
 
tumors. Singlet oxygen is extremely polarized zwitterion hence lifetime is very 
short around microseconds in organic solvent and shorter in aqueous 
environment. This relatively short lifetime let its activity in restricted area about 
maximum 30 nm in diameter
66
. These small diameters ensure the localized 
damage to cells. Since research results shows that Type II mechanism is more 
often the case for PDT action, leading role for cell damage belongs to singlet 
oxygen. It worth to note that for variety of photosensitizer, energy transfer 
between photosensitizer and molecular oxygen can occur even photosensitizer 
is in singlet state. The reason for energy transfer can be the large energy gap 
between singlet state and triplet state while singlet state of photosensitizer has 
long enough lifetimes for the process. Although it is hard to measure singlet 
oxygen’s ability to damage tissue because of its reactivity and short lifetime, 
there are many studies propose direct and indirect evidence for the method.  
Singlet oxygen exposure to tissues can be determined by using trap molecules 
experimentally
62,67
.  
There are also different types of light sources available for PDT action 
but the most convenient ones are the lasers. Light source is important since 
proper wavelength needed for application and dosimetry of light shouldn’t be 
analyzed uncomplicatedly. Also it can be helpful to determine tissue depth for 
the action
68
. 
 
1.1.3 Biological Response 
In the Fig.5, PDT mechanism is illustrated through various scenario 
possibilities
69
. Tumor damage which is caused by reactive oxygen species could  
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Figure 5. Biological Response toward PDT action
69
 Copyright © 2008, 
Springer-Milan Adapted with permission 
kill cells through necrosis/apoptosis or cells can survive. Three different 
mechanisms are mostly recognized for antitumor outcome of PDT action
8
. 
Direct tumor damage can be said as first situation in which singlet oxygen 
species killed malignant cells directly. In other case damage is given to 
vasculature causing infraction in malignant tissues. In the last case, immune 
response to tumor cells can be evoked and the damage will be given by immune 
system
70
. Contributions of the each case to tumor destruction have been hard to 
clarify but it is sure that all of them are needed for control of the process
8
. 
Different studies claimed that necrosis will be dominant at optimum conditions 
in which adequate light exposure and phosensitizers amount are available. In 
other possibilities, it could be said that cells will undergo apoptosis mechanism 
of death. Apoptosis and necrosis mechanism are very different process. 
Necrosis has known longer than apoptosis in literature. Apoptosis is cell suicide 
mechanism or programmed cell death toward various effects based on genetic 
in sum. Necrosis is early death of cells as a response toward generally external 
effects and accepted as not beneficial process compared to apoptosis
71
. 
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There are many examples reveal the damage to tumor cells are succeed 
through vascular destruction. Tumor cells as healthy cells need nutrition 
supplied from blood vessels to survive even more than healthy cells. Growth 
factors determine through signals which are produced in tissue the blood 
vessels progression. Destruction of vasculature system in targeted tissue is 
promising method for malignant diseases. Hypoxia and anoxia resulting from 
microvascular collapse are reported in tumor destruction process during PDT 
action
72,73,74. There are various studies confirming different photosensitizer’s 
vascular limitation, thrombus generation and decrease in malignant growth. 
VEGF and other angionic factors are affected during PDT action
75
. Further 
studies are needed in order to comprehend the vasculator damage mechanism as 
a result of PDT.  
Many important scientists have been showed the direct effect of cell 
killing through PDT in which optimum conditions are supplied and sufficient 
reactive oxygen species are generated
76
. Large part of the cell death is 
performed by the vascular shutdown which leads deficiency of nutrition and 
oxygen in tumor cells. Photofrin is significant for this concept although it 
destruct widely tissues around the tumor in unselective manner
75,
. Different 
parameters are effective tumor damage and precluding the direct malignant cell 
killing. Proximity of the blood vessels is one of the factors that affect the direct 
cell killing. Depending on the administration methods, distribution of the 
photosensitizers will vary. Heterogeneous distributions also limit the direct cell 
killing process in tumor tissue. Another limitation occurs from oxygen 
deficiency in tumor tissue
26,77,78
. Many reasons can be listed but most important 
one can be said PDT effects which decrease the amount oxygen concentration
79
 
depending on the light fluence rate. Direct tumor is not completely negligible 
part of PDT action. It is a part of the all process, enable us understand its 
features and close us to solve its full mechanism
80
.  
Last tumor damage mechanism is the evoking immune response. 
However these processes have not been recognized fully, scientists are claiming 
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that PDT action effects immune system
81
. Both activation and suppression is 
observed in different type of the photosensitizers present. Activation of specific 
immune response towards tumor tissue is highlighted research subject in 
literature
82
. It can be very useful factor in order to fight tumor tissue more 
effectively. On the contrary, depending on the complex parameters, scientists 
have also reported suppression of immune response during PDT action
83
. 
Further investigations are needed to examine potential of PDT as systemic 
immune therapy
84
. 
 
1.2 Activatable PDT Agent 
Depending on the different conditions of tumor tissues than healthy 
tissues, new methodologies are improved in order to enhance sensitivity of PDT 
method. Administration of photosensitizer in targeted region could decrease the 
side effects of PDT action. With the purpose of targeting, several methods can 
be applied as antibody targeted, protein conjugated, targeting ligand 
modification and vascular objected. Third generations of photosensitizers are 
employed by modification of second generation of photosensitizer for targeted 
purposes. The need for third generation of photosensitizer arouse from the 
limitations of previous generation. Healthy tissue damage and restricted 
feasibility of method because of the delivery challenge are significant driving 
force for researches to improve new more sensitive techniques
6
. 
Antibody targeting delivery has been progressed for decades
85,86,87
. 
However, there is not any example of clinical trials for this established 
technique yet. Through the recognition of overexpressed antigen over cells, this 
method let photosensitizer to locate targeted tissue. Although promising results 
obtained from various studies
88
, this method has some drawbacks which affect 
the efficiency of PDT action. Because of the high molecular weights of the 
antibodies compared to photosensitizers, function and the amount of the 
photosensitizer could be confined to some extent. Antibodies are not the only 
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option for targeted PDT action. Also other kind of proteins could be used in 
order to increase therapeutic effects of PDT
89
.  
Another promising method is small ligand conjugation
90
. In this 
technique, small ligands recognize overexpressed molecules over the cell. 
Folate molecules which are overexpressed in malignant cells can be example of 
this method. Coupling of the folate molecule with photosensitizer will increase 
the uptake rate of photosensitizer into cancer cells
91
. Peptides and molecular 
sugar are also used for targeting function in PDT
92
. VEGF and RGD could be 
listed for peptide targeting
93
. Nucleic acid based aptamers
94
 are also subject to 
targeting. Various type of cancer is interest of the targeted PDT mechanism. 
These methods can be manipulated for the purposes. For example, vasculature 
of the tumor cells can be targeted instead of targeting tumor cells. Due to 
deficiency of the nutrition and oxygen, tumor cell will be killed through indirect 
targeting. Prohibition of the activation of photosensitizer in healthy tissue will 
be the significant advantage of the targeted PDT
95
. Reducing the damage 
toward the healthy tissue is important for patient’s life standards. 
Manipulating different mechanism as photophysical properties of 
photosensitizer, deactivation can be achieved. Through designing activation 
process within malignant cells, photosensitizer could be used to destruct tumor 
tissue only. For this purposes, many different type of molecules are proposed 
and called quencher which change the excitation characteristic of 
photosensitizer. Quenching methods can use of Förster resonance energy 
transfer (FRET), photoinduced electron transfer (PeT) and self quenching
96
.  
FRET deactivation
97
 process is applied through conjugation of 
chromophore to photosensitizer by linker molecules. FRET is energy transfer 
process which occur nanometer range. Chromophore as quencher absorbs the 
energy photosensitizer emits as illustrated in Fig. 6. For this energy transfer,  
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Figure 6. FRET deactivated Photosensitizer design 
 
chromophore need to absorb in the range which photosensitizer emits. Also 
linker length is important parameter in order to determine efficiency of 
quencher. Longer linker could decrease energy transfer yield due to the FRET 
distance limitations based on spectral overlap between quencher and 
photosensitizer. After effective FRET process, fluorescence of the 
photosensitizer will be quenched thus; singlet oxygen generation will decrease 
dramatically. In Fig.6, compound 15
97
 (pyropheophorbide-a) is used as 
photosensitizer. Fluorescence rate is used instead of singlet oxygen rate, which 
is relatively easier to measure. In addition to this design, self-quenching could 
be employed as other methodology for FRET process. Although using more 
photosensitizer will increase singlet oxygen rate, solubility problems could 
arouse through these designs with unpredicted challenges which can affect the 
reactive oxygen species proportion. FRET deactivation method has shown 
promising results
97
.  
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Figure 7. Mechanism target-specific activatable probes
98
 Copyright © 2008, 
Rights Managed by Nature Publishing Group, Adapted with permission 
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The method in which direct use of probe is applied has disadvantages like 
low tumor to normal cell ratio and background signal. Through activatable 
photosensitizer design, all of the drawback previously mentioned can be 
minimized. Illustration of these concepts
98
 and also probe-antibody conjugate in 
cells is available in Fig. 7 which is reported by Urano et al.. This representation 
is an example for breast cancer targeted methodology. HER2 receptor is 
overexpressed over the tumor cell. Through using monoclonal antibody 
trastuzumab, targeting is accomplished. 
 
 
Figure 8. pH-activatable Bodipy derivatives 
 
In Fig. 8, an example of off-on switching (compound 16) is reported. 
Manipulating PeT process, chromophore moiety gets activated in acidic 
medium. Although this design is used for imaging, it can be modified for PDT 
action. Activation is achieved based on the pH difference between lysosome 
(pH 5-6) and cytoplasma (pH 7.4). While PeT process is occurring, energy 
transfer will not be possible from photosensitizer to molecular oxygen. Hence 
reactive oxygen species could not be produced. Deactivation of the PeT route 
through acidic environment in this case will enable singlet oxygen generation
98
.  
Also other photosensitizer
99
 which is activated through two different 
parameters is planned as proof of principle by Akkaya et al. Crown ether 
moiety is conjugated to iodinated Bodipy core. PeT process is manipulated in 
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the crown part of the design. Pyridine moieties are united through third and fifth 
position through knoevenagel reaction in order to sense the pH difference 
between normal tissue and tumor tissues. Design is illustrated in Fig. 9 as 
compound 17.  
 
Figure 9. Logic gate integrated PDT agent 
 
Based on pH and Na
+
 concentration, AND logic gate is employed as an 
example of activatable PDT agent. This photosensitizer gets activated in high 
Na
+
 concentration and acidic environment. If either of them is not case, singlet 
oxygen level in medium is negligible
99
.  
 
1.3 Glutathione Sensing and Signaling 
Thiol derivatives such as cysteine (Cys), homocysteine (Hcy) and 
glutathione (GSH) have important roles in biological activity thus researches 
have been carried out in order to develop sensitive thiol probes for years. Many 
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different methods have been improved for these purposes. Different type of 
reaction mechanism as cleavage and addition has been used for progress. Each 
of the thiol derivatives mentioned before have different and significant 
properties
100
. GSH sensing and its mechanism will be our primary subject since 
its concentration is higher in tumor cells up to 50 folds
101,102
 than healthy cells 
and could be used for PDT action. In order to understand sensing mechanism 
which used our study, we need to understand firstly PeT mechanism.  
 
1.3.1 Photoinduced Electron Transfer and Examples 
Photoinduced electron transfer (PET) is a signaling phenomenon which 
relies on emission intensity. In certain cases, excited molecule can transfer an 
electron from other potential donor to its low lying orbital before relaxation 
occurs. The process which is called photoinduced electron transfer has a major 
role in photosynthesis and is well studied. PET process can be divided into two 
categories depending on the electron transfer direction between fluorophore and 
receptor. If donor is fluorophore, process is called oxidative (reverse) PET. In 
generally seen examples in literature, acceptor is fluorophore as in the case in 
Fig. 10 and it is called reductive PET
103
. 
 
Figure 10. Principle of cation recognition by fluorescent PET sensors
103
 
Copyright © 2000, Elsevier, Adapted with permission 
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Fig. 10 demonstrates working principal for PET mechanism in 
fluoroionophores. In this design, receptor part includes electron donating 
groups. Due to excitation of fluorophore, an electron from the highest occupied 
molecular orbital (HOMO) transferred to the lowest unoccupied molecular 
orbital (LUMO). Electron transfer blocks usual relaxation pathway of excited 
fluorophore. This route causes quenching of fluorescence until energy level of 
HOMO of the receptor is lowered through binding of analyte. PET process is 
disturbed and this let increase in fluorescence
103
.  
Beside major role in photochemical reactions in photosynthesis
104
, PET is 
widely admitted in fluorescent sensor for diverse of analyte as cations, anion 
and neutral molecules
105,106
. Both of excitation and emission accomplished 
through fluorophore module. Receptor module is used to control for 
complexation/ decomplexation with analyte molecule. Spacer parts of the 
design help to separate fluorophore and receptor but also hold them close 
enough for electron transfer. These mechanisms can be utilized to develop 
designs for on- off and off-on systems. In Fig.10 shows control over PET 
mechanism by using analyte molecules. This design is an example of off-on 
type signaling system. Upon addition of analyte, fluorescence increases which 
sense existence of our analyte molecule
107
.  
Figure 11. Crown containing, podand based and calixarene based PET sensors. 
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There are many fluorescent chemosensors designed according to this principle. 
Selectivity for specific ions achieved through appropriate selection of 
recognition moiety. A typical example is crown ether compounds as a 
recognition moiety as in Fig. 11, compound 18
108
 other example compound 
19
109
 is podand based PET sensor which is selective for Zn
2+
 because of the 
strong affinity towards to nitrogen atom. Unfortunately, this sensor is working 
in very limited pH and also sensitive to Cu (II). In the last design
110
 by Akkaya 
group et al., a Bodipy fluorophore is attached to calix[4]arene which is donor 
part of the design because of the oxygen lone pairs. Protonation of this oxygen 
made PET route less favorable. With changing pH, up to 10 –fold increase will 
be observed in fluorescence.  
There are also different examples
111
 leading us to discover oxidative PET 
process in which fluorophore act as an electron donor towards electron deficient 
receptor. One of the examples is reported as a thiol sensor by Nagano
112
 
illustrated in Figure 4. compound 21. 
  
Figure 12. Oxidative PET sensor
112
 Copyright © 2007, American Chemical 
Society. Adapted with permission 
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In this particular example molecule 21, maleimide moiety is utilized as a PET 
acceptor whereas Bodipy is as fluorophore. Thiol reacts with maleimide and 
350-fold increase in fluorescence signal is observed. Also Nagano group study 
effect of distance between donor and acceptor through using both meta and 
para- maleimide bound structures. Research shows that Omaleimide is the most 
efficient PET acceptor than metamaleimide and para-maleimide. Results lead us 
to conclude that while groups are getting closer, PET is getting more 
effective
112
.  
 
1.3.2 Photoinduced Charge Transfer 
One of the other mechanisms which are used to manipulate fluorescence 
characteristic of molecules is Photoinduced Charge Transfer. Principles of PCT 
were first introduced in explanation for increase acidity of phenol molecule
113
. 
On the other hand, generalization of these ideas and utilization in metal sensing 
could not be understood until Valeur
114,115,116
. In PCT, spacer unit is removed 
between receptor and signaling modules. Fluorophore is directly integrated with 
receptor that is part of π-electron system of the fluorophore. Either fluorophore 
or receptor should be electron rich and other one electron poor. Excitation of 
this integrated system leads to redistribution of electron density then to 
substantial dipole which causes Intramolecular charge transfer from donor to 
acceptor. Interaction between receptor and target molecule results either 
stabilization of HOMO or LUMO level or destabilization. These energy levels 
can act independently each other since one of them can be stabilized and other 
one destabilized, it depends on the molecular structure. These stabilization / 
destabilization arrange energy difference between HOMO and LUMO levels 
that can be followed over the reflection over emission or absorption spectra of 
molecules. Not only electron donor/ acceptor characteristic of receptor but also 
target molecules ionic features are important for determining red/ blue spectral 
shifts
117
. 
Excited state of fluorophore has similar appearance with resonance 
structure of molecules. Photophysical properties of the fluorophore will be 
25 
 
changed upon interaction with cation/ anion due to the ion effects on efficiency 
of Intramolecular charge transfer. For instance electron donating group (amino 
group) can be part of the fluorophore system and interaction with cation will 
reduce electron donor nature of it. This change will prepare a basis for 
reduction of conjugation that can be proved through blue shift. Dipole 
interactions can be used to illustrate the photophysical changes upon cation 
binding. Interaction between electron donating groups and cation will 
destabilize the excited state which results an increase energy gap between S1 
and S0 energy levels. Due to reciprocal relation between energy and 
wavelength, this increase in energy will decrease wavelength. Existence of 
analyte (targeting moiety) can be turn to a signal through blue shift as 
illustrated in Fig. 13
103
.  
 
 
Figure 13. Spectral displacements of PCT sensors
103
. Copyright © 2000, 
Elsevier, Adapted with permission 
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On the contrary, interaction between cation and acceptor group (carbonyl) 
will be different. This will increase the electron withdrawing nature of this 
group and excited state will stabilized more due to charge-dipole interaction. If 
excited state is analyzed, we need to consider resonance structure of the 
acceptor group, carbonyl group will be negatively charged which lead 
stabilization of excited state with the help of interaction between cation and 
acceptor group. Stabilization will decrease the energy gap between S1 and S0. In 
this example signal of the analyte will be obtained through red shift in both 
absorption and emission spectra as a result of the decrease in energy gap as in 
Fig.13.
103
 In PCT, both of the fluorescence and absorption spectra will shift 
towards the same direction either of blue or red shift. Effects of charge and size 
of the cation cannot be ignored in this process
117
.  
Many fluoroionophores have been designed according to these principles 
including azacrown groups as a cation receptor conjugated to an electron 
withdrawing groups to sense cation
116,118
. 
 
 
Figure 14. Crown containing PCT sensors. 
 
Upon cation binding compounds 22
119
 and 23
120
 show blue shift in both 
absorption and emission spectra according to PCT mechanism in Fig. 14. There 
is also many other examples.  
Other fluorescent thiol (compound 24
121
) probe is introduced by Lin et 
al.. Diethylaminocoumarin is used as fluorophore moiety in Fig. 15. 
Fluorophore also conjugated a,b-unsaturated ketone in order to sense thiol 
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groups. Through pyridine moiety ICT can draw out from diethyl amino group 
to pyridine group. After interaction with the thiol groups, conjugation of the 
pyridine group to the chromophore will be blocked also ICT process too.  
 
 
Figure 15. ICT dependent thiol Probe 
 
Compound 24 shows low fluorescence intensity compared to 24-thiol 
compound. The reason can be non-fluorescent ICT mode. This difference let 
the use of this compound as off-on probe for thiol groups
121
. 
 
1.3.3 FRET Based Sensing 
Förster resonance energy transfer (FRET) or through space energy 
transfer is a nonradiative process which does not depend on the orbital 
interaction. An excited state donor transfers energy to a proximal ground state 
acceptor through long range dipole-dipole interactions. In this mechanism, it is 
more likely to observe larger separation between donor and acceptor molecules. 
 
Figure 16. Schematic representation Förster-type (through-space) energy 
transfer. 
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The spectral overlap
122,123 
between donor emission and acceptor absorbance is 
significantly important while there is no conjugation between donor and 
acceptor units as in Fig. 16.  
Other deactivation process
124
 will compete with energy transfer process 
since it is through bond. Internal conversion through vibrational relaxation, 
quantum yield of donor are a few examples of photophysical properties of 
chromophore that can cause deactivation process.  
Donor (D) and acceptor (A) units separated by a distance of R, energy 
transfer rate (kFRET) can be defined by using Förster distance (Ro) which is the 
distance between donor and acceptor units at which half of excited molecules 
transfer energy to acceptor molecules as in the equation below.  
 
Ro = 9.78 x 10
3
 [2 n-4 QD J() ]                                             (equation 2) 
kFRET = [ 900 (ln10) 
2
 D J() ] / [128 
5
 n 
4
 N D R
6
DA ]    (equation 3) 
 
In these equations,  represents the orientation factor between excited 
state donor and ground state acceptor where it is related with dipole-dipole 
interaction of donor and acceptor units. n stands for refractive index of the 
solvent where QD stands for the quantum yield of donor in the absence of 
acceptor unit. J is Förster overlap integral of donor emission and acceptor 
absorbance, QD  is lifetime of excited donor without of acceptor unit. Last of all 
RDA is the distance between donor and acceptor. As it is in 6
th
 power, 
importance of distance is obvious
41
. Generally it should be between 10-100 Å 
to be effective
125
.  
In Fig. 6, compound 15 is an example for manipulation of FRET process. 
Another example is compound 25
126
 which is proposed by Karuso et al. in Fig. 
17.Disulfide linker is used here for thiol sensitivity. Fluorescein and Rhodamine  
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Figure 17. FRET based thiol sensing probe based chromophores used for 
energy transfer. 
Upon addition of GSH, cleavage of the disulfide bond occurs which lead 
diminish in FRET yield and enhance fluorescence intensity at 520nm
126
. 
 
1.3.4 Other Process and Examples 
GSH structure
100
 is demonstrated in Fig.18. Different types of 
methodologies for sensing mechanism have been developed. One of them is 
using maleimide moiety conjugated to different molecules. One of the examples 
for this method has been shown in Fig.12. Michael addition is taking place 
through manipulating PeT process
112
. 
 
Figure 18. GSH structure 
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Figure 19. Structures of Thiol Probes 
One of the examples is available in Fig. 19 as compound 26
127
 for 
quinine-methide type rearrangement due to results obtained from experiments. 
Huang et al. proposed new fluorimetric probe for detection of biological 
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probes. Spontaneous and irreversible reaction takes place with the thiol 
derivatives. These probe could be used various purpose for sensing glutathione 
over amino acids. 
Another method is based on displacement approach with the example 
compound 27. Lam et al. presented a neutral trinuclear heterobimetallic cyano-
bridged Ru (II)/Pt (II) complex, cis-Ru(phen)2-[CN-Pt(DMSO)Cl2]2 an 
example
128
 for thiol sensing. Emission of the complex is diminished through the 
re-organization due to cyano groups. After addition of thiol group, Pt and thiol 
are coordinated which lead the increase of the emission again. GSH could be 
determined using this mechanism depending on the emission intensity change. 
GSH could be sensed through cleavage of sulfonamide and sulfonate ester 
as in the case for compound 28. Maeda et al. propose combination of the 
Rhodamine dye and the 2, 4-dinitrobenzenesulfonyl (DNBS) moiety
129
. 
Fluorescence intensity enhance after the cleavage of the DNBS group. The 
probe is very sensitive towards the GSH and gives quick response.  
The last example stands for Se-N cleavage based sensing mechanism. 
Tang et al. reported compound 29, fluorescence probe for glutathione sensing 
which is based on combination of Rhodamine dye and Se-N bonds
130
. 
Fluorescence intensity increases through the cleavage of the Se-N bonds. 
Sensing could be achieved by manipulating fluorescence intensity.  
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CHAPTER 2 
 
EXPERIMENTAL 
 
2.1. General 
 
All chemicals and solvents obtained from Sigma-Aldrich were used 
without further purification. Reactions were monitored by thin layer 
chromatography using Merck TLC Silica gel 60 F254. Chromatography on silica 
gel was performed over Merck Silica gel 60 (particle size: 0.040-0.063 mm, 
230-400 mesh ASTM). 
1
H NMR and 
13
C NMR spectra were recorded at room temperature on 
Bruker DPX-400 (operating at 400 MHz for 
1
H NMR and 100 MHz for 
13
C 
NMR) in CDCl3 with tetramethylsilane (TMS) as internal standard. Coupling 
constants (J values) are given in Hz and chemical shifts are given in parts per 
million (ppm). Splitting patterns are designated as s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), and p (pentet). Mass spectra were recorded 
with Agilent Technologies 6224 TOF LC/MS 
Absorption spectra in solution were obtained using a Varian Cary-100 
and Varian Cary 5000 UV-VIS-NIR absorption 
spectrophotometer.Fluorescence measurements were done on a Varian Eclipse 
spectrofluometer. Spectrophotometric grade solvents were used for 
spectroscopy experiments. Bodipy dyes are synthesized as activatable 
photosensitizer for photodynamic therapy. For water solubility 3,4,5-tris(2-(2-
(2-methoxyethoxy)ethoxy)ethoxy) benzaldehyde
23
 were synthesized according 
to literature.  
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2.2. Synthesis of Target Molecules 
 
2.2.1. Synthesis of Compound 30 
 
Figure 20. Synthesis of Compound 30 
To a stirred argon degassed solution of CH2Cl2 (300 mL) for 30 min, 2,4-
dimethyl pyrrole (12.3 mmol, 1.17 g) and 4-hydroxybenzaldehyde (6.0 mmol, 
0.75 g) were added in it under argon atmosphere. 1-2 drops of TFA was added, 
mixture stirred for overnight at room temperature. Then p-Chloranil (6.0 mmol, 
0.77 g) in 30 ml CH2Cl2 was added to the reaction mixture, stirring was 
continued for 2-3 h. After 2-3 h, Et3N (5 mL) and BF3.OEt2 (5 mL) were 
introduced. 100 mL of water was added into the reaction mixture and then 
extracted into the CHCl3 (3 x 100 mL). Na2SO4 was used as a drying agent. The 
organic layer was concentrated in vacuo and the crude product was purified by 
column chromatography packed with silica gel using CHCl3 as the eluant. 
Orange-Red solid was obtained (0.65 g, 32 %). 
1
H NMR (400 MHz, CDCl3): H 
7.14 (d, J = 8.2 Hz, 2H, ArH), 6.97 (d, J = 8.5 Hz, 2H, ArH), 6.00 (s, 2H, ArH), 
2.57 (s, 6H, CH3), 1.46 (s, 6H, CH3). 
13
C NMR (100 MHz, CDCl3): C 156.36, 
155.32, 143.19, 141.80, 132.02, 129.39, 127.15, 121.16, 116.12, 14.57 ppm. 
MS (TOF- ESI): m/z: Calcd for C19H19BF2N2O: 338.1558 [M-H]
-
, Found: 
338.1493 [M-H]
-, Δ=8.71 ppm. 
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2.2.2. Synthesis of Compound 31 
 
Figure 21. Synthesis of Compound 31 
Compound 30 (0.176 mmol, 60 mg) is dissolved in 20 mL mixture 
(DMF/DCM, 1:1, v/v). Then, N-Bromosuccinimide (0.37 mmol, 66mg) is 
dissolved in DCM (10 mL) and added dropwise to reaction mixture. The 
mixture is stirred at room temperature. The reaction is monitored by TLC. After 
finishing starting material, reaction is stopped by adding 100 mL of water.  The 
mixture is extracted into DCM (3x 100 mL). The organic phase was dried over 
Na2SO4 and concentrated in vacuo. Then crude product was purified by silica 
gel column chromatography (Acetone/ Hexane, 1:4, v/v). Red solid was 
obtained (0.084 g, 95%). 
1
H NMR (400 MHz, CDCl3): H 7.13 (d, J = 8.97 Hz, 
2H, ArH), 7.01 (d, J = 8.5 Hz, 2H, ArH), 5.18 (s, H, OH), 2.62 (s, 6H, CH3), 
1.47 (s, 6H, CH3). 
13
C NMR (100 MHz, CDCl3): C 161.2, 157.33, 146.87, 
144.69, 134.71, 132.89 128.95, 120.16, 114.52, 17.49 ppm. MS (TOF- ESI): 
m/z: Calcd for C19H17BBr2F2N2O: 493.9769 [M-H]
- 
, Found: 493.9713 [M-H]
-
 , 
Δ=3.87 ppm.  
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2.2.3. Synthesis of Compound 32 
 
 
Figure 22. Synthesis of Compound 32 
Compound 31 (0.187 mmol, 93 mg) and 3,4,5-tris(2-(2-(2-
methoxyethoxy)ethoxy)ethoxy) benzaldehyde (0.393 mmol, 233 mg)
 
 were 
added into a 100 mL round-bottomed flask equipped with a Dean-Stark 
apparatus. 40 mL of benzene, acetic acid (0.2 mL) and piperidine (0.2 mL) 
were added and mixture were stirred at reflux temperature. The reaction was 
monitored by TLC and continued until starting material was finished. Water 
(100 mL) was added to reaction mixture which was cooled to room 
temperature. Mixture was extracted into DCM (3x 100 mL). The organic phase 
was dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by silica gel column chromatography (DCM/ MeOH, 95:5, v/v). The 
product was collected as green solid (130 mg, 42 %). 
1
H NMR (400 MHz, 
CDCl3): H 7.90 (d, J = 16.5 Hz, 2H, CH), 7.44 (d, J = 16.6 Hz, 2H, CH), 7.09 
(d, J = 8.3 Hz, 2H, ArH), 6.94 (d, J = 8.3 Hz, 2H, ArH), 6.84 (s, 4H, ArH), 4.22 
(t, J = 4.9 Hz, 14H, OCH2), 3.88 (t, J = 4.9 Hz, 8H, OCH2), 3.83 (t, J = 4.9 Hz 
,4H, OCH2), 3.78 – 3.73 (m, 14H, OCH2), 3.71 – 3.62 (m, 28H, OCH2), 3.58 
(dd, J = 6.0, 3.4 Hz, 4H, OCH2), 3.55 – 3.51 (m, 8H, OCH2), 3.40 (s, 6H, 
OCH3), 3.36 (s, 10H, OCH3), 1.41 (s, 6H, CH3). 
13
C NMR (100 MHz, CDCl3): 
C 157.75, 152.82, 147.78, 141.16, 140.02, 138.64, 133.07, 132.43, 129.63, 
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126.15, 117.36, 116.45, 110.09, 107.54, 72.50, 71.92, 70.63, 69.74, 69.02, 
58.98, 14.08 ppm. MS (TOF- ESI): m/z: Calcd for C75H109BBr2F2N2O25: 
1642.5747 [M-H]
-
, Found: 1642.5585 [M-H]
-
 , Δ=9.86 ppm.  
 
2.2.4. Synthesis of Compound 33 
 
 
Figure 23. Synthesis of Compound 33 
Compound 32 (0.24 mmol, 400 mg) was dissolved in dry THF (30 mL). 
Then triethylamine (0.12 mL) was added and stirred for 30 min at room 
temperature. A solution of 2, 4-dinitrobenzenesulfonyl chloride (0.77 mmol, 
200 mg) in dry THF (20 mL) was added dropwise at 0 ◦C. The mixture was 
heated to 40 ◦C and stirred for overnight. Then reaction was cooled to room 
temperature and solvent was evaporated. Crude product was purified by silica 
gel column chromatography (DCM/ MeOH, 95:5, v/v). The product was 
collected as pale green solid (274 mg, 60 %). 
1
H NMR (400 MHz, CDCl3): H  
8.71 (s, 1H), 8.57 (dd, J = 8.6, 2.2 Hz, 1H, ArH), 8.26 (d, J = 8.6 Hz, 1H, ArH), 
7.98 (d, J = 16.5 Hz, 2H, CH), 7.50 (s, 1H), 7.47 – 7.42 (m, 2H, CH), 7.41 – 
7.31 (m, 3H, ArH), 6.86 (s, 4H, ArH), 4.22 (dt, J = 7.5, 5.4 Hz, 15H, OCH2), 
3.90 – 3.84 (m, 9H, OCH2), 3.84 – 3.79 (m, 6H, OCH2), 3.77 – 3.70 (m, 15H, 
OCH2), 3.68 – 3.60 (m, 30H, OCH2), 3.59 – 3.54 (m, 5H, OCH2), 3.53 (dt, J = 
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4.5, 3.9 Hz, 12H, OCH2), 3.39 (s, 5H, OCH3), 3.36 (s, 12H, OCH3), 1.38 (s, 6H. 
CH3). 
13
C NMR (100 MHz, CDCl3): C 152.90 , 151.16, 149.54, 148.97, 
140.46, 140.09, 136.67, 135.01, 133.77, 133.28, 132.09, 130.69, 126.44, 
123.34, 120.52, 116.85, 111.10, 107.79, 72.51, 71.93, 70.63, 69.71, 69.09, 
58.99, 14.02 ppm.  
 
2.2.5. Synthesis of Compound 34 
 
 
Figure  24. Synthesis of Compound 34 
To a stirred argon degassed solution of 300 mL CH2Cl2 for 30 min, 2,4-
dimethyl pyrrole (12.3 mmol, 1.17 g) and 2-hydroxybenzaldehyde (6.0 mmol, 
0.75 g) were added in it under argon atmosphere. 1-2 drops of TFA is added, 
mixture stirred for overnight at room temperature. Then p-Chloroaniline (6.0 
mmol, 0.77 g) in 30 ml CH2Cl2 is added to the reaction mixture, stirring was 
continued for 2-3 h. After 2-3 h, Et3N (5 mL) and BF3.OEt2 (5 mL) were 
introduced. 100 mL of water was added into the reaction mixture and then 
extracted into the CHCl3 (3 x 100 mL). Na2SO4 was used as a drying agent. The 
organic layer was concentrated in vacuo and the crude product was purified by 
column chromatography packed with silica gel using (CHCl3) as the eluant. 
Orange solid (0.51 g, 25%). 
1
H NMR (400 MHz, CDCl3): H 7.40 (t, J = 7.2 Hz, 
1H, ArH), 7.14 (d, J = 6.3 Hz, 1H, ArH), 7.08 (t, J = 7.4 Hz, 1H, ArH), 7.03 (d, 
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J = 8.2 Hz, 1H, ArH), 6.02 (s, 2H, ArH), 2.58 (s, 6H, CH3), 1.53 (s, 6H, CH3). 
13
C NMR (100 MHz, CDCl3): C 156.26, 152.29, 142.79, 135.09, 131.11, 
129.16, 121.68, 121.55, 120.95, 116.54, 14.64, 13.72 ppm. MS (TOF- ESI): 
m/z: Calcd for C19H19BF2N2O: 338.1558 [M-H]
-
, Found: 338.1523 [M-H]
-
, 
Δ=0.1 ppm. 
 
2.2.6. Synthesis of Compound 35 
 
 
Figure 25. Synthesis of Compound 35 
Compound 34 (0.176 mmol, 60 mg) is dissolved in 20 mL mixture 
(DMF/DCM, 1:1, v/v). Then, N-Bromosuccinimide (0.37 mmol, 66mg) is 
dissolved in DCM (10 mL) and added dropwise to reaction mixture. The 
mixture is stirred at room temperature. The reaction is monitored by TLC. After 
finishing starting material, reaction is stopped by adding 100 mL of water.  The 
mixture is extracted into DCM (3x 100 mL). The organic phase was dried over 
Na2SO4 and concentrated in vacuo. Then crude product was purified by silica 
gel column chromatography (EtOAc/ Hexane, 1:6, v/v). Red solid was obtained 
(0.031 g, 35%). 
1
H NMR (400 MHz, CDCl3): H  7.45 (dt, J = 8.7, 4.4 Hz, 1H, 
ArH), 7.11 (d, J = 4.3 Hz, 2H, ArH), 7.04 (d, J = 8.3 Hz, 1H, ArH), 4.96 (s, 1H, 
OH), 2.63 (s, 6H, CH3), 1.53 (s, 6H, CH3). 
13
C NMR (100 MHz, CDCl3): C 
131.63, 129.09, 122.06, 120.57, 116.78, 31.60, 29.21, 22.51, 14.18, 13.75, 
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13.02, 1.01 ppm. MS (TOF- ESI): m/z: Calcd for C19H17BBr2F2N2O: 493.9769 
[M-H]
- 
, Found: 493.9772 [M-H]
-
 , Δ=5.47 ppm.  
 
2.2.7. Synthesis of Compound 36 
 
 
Figure 26. Synthesis of Compound 36 
Compound 35 (0.193 mmol, 96 mg) and 3,4,5-tris(2-(2-(2-
methoxyethoxy)ethoxy)ethoxy) benzaldehyde (0.405 mmol, 240 mg) were 
added into a 100 mL round-bottomed flask equipped with a Dean-Stark 
apparatus. 40 mL of benzene, acetic acid (0.2 mL) and piperidine (0.2 mL) 
were added and mixture was stirred at reflux temperature. The reaction was 
monitored by TLC and continued until starting material was finished. Water 
(100 mL) was added to reaction mixture which was cooled to room 
temperature. Mixture was extracted into DCM (3x 100 mL). The organic phase 
was dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by silica gel column chromatography (DCM/ MeOH, 95:5, v/v). The 
product was collected as green solid ( 134 mg, 41 %). 
1
H NMR (400 MHz, 
CDCl3): H 7.96 (d, J = 16.5 Hz, 2H, CH), 7.33 (dd, J = 9.7, 5.3 Hz, 2H, ArH), 
7.00 (s, 2H, ArH), 6.97 (d, J = 4.5 Hz, 2H, ArH), 6.88 (s, 2H, ArH), 4.26 (t, J = 
4.7 Hz, 8H, OCH2), 4.18 (dd, J = 10.3, 5.1 Hz, 4H, OCH2), 3.88 (t, J = 4.8 Hz, 
10H, OCH2), 3.81 (t, J = 5.0 Hz, 4H, OCH2), 3.74 (dd, J = 8.8, 3.8 Hz, 14H, 
40 
 
OCH2), 3.70 – 3.61 (m, 28H, OCH2), 3.55 (dd, J = 7.6, 3.5 Hz, 6H, OCH2), 
3.54 – 3.50 (m, 10H, OCH2), 3.38 (s, 6H, OCH3), 3.35 (s, 10H, OCH3), 1.26 (s, 
6H, CH3). 
13
C NMR (100 MHz, CDCl3): C 213.74, 153.15, 152.74, 148.04, 
141.26, 140.20, 139.25, 132.64, 132.09, 131.50, 129.12, 121.25, 120.82, 
116.90, 116.59, 110.53, 107.78, 72.45, 71.90, 70.81, 70.66, 70.52, 69.70, 69.03, 
58.99, 12.88 ppm. MS (TOF- ESI): m/z: Calcd for C75H109BBr2F2N2O25: 
1642.5747 [M-H]
-
, Found: 1642.5604 [M-H]
-
 , Δ=8.72 ppm.  
 
2.2.8. Synthesis of Compound 37 
 
 
Figure 27. Synthesis of Compound 37 
Compound 36 (0.14 mmol, 230 mg) was dissolved in dry THF (30 mL). 
Then triethylamine (0.12 mL) was added and stirred for 30 min at room 
temperature. A solution of 2, 4-dinitrobenzenesulfonyl chloride (0.77 mmol, 
200 mg) in dry THF (20 mL) was added dropwise at 0 ◦C. The mixture was 
heated to 40 ◦C and stirred for overnight. Then reaction was cooled to room 
temperature and solvent was evaporated. Crude product was purified by silica 
gel column chromatography (DCM/ MeOH, 95:5, v/v). The product was 
collected as pale green solid (130 mg, 35 %). 
1
H NMR (400 MHz, CDCl3): H 
8.82 (d, J = 2.6 Hz, 1H, ArH), 8.59 (s, 1H, ArH), 8.32 (dd, J = 9.1, 2.6 Hz, 1H, 
ArH), 8.25 (dd, J = 8.6, 2.1 Hz, 1H, ArH), 7.94 (d, J = 16 Hz, 2H, CH), 7.77 (d, 
J = 8.6 Hz, 1H, ArH), 7.72 (t, J = 7.8 Hz, 1H, ArH), 7.67 – 7.60 (m, 1H, ArH), 
7.55 (t, J = 7.5 Hz, 1H, ArH), 7.46 (d, J = 5.4 Hz, 1H, ArH), 7.41 (s, 1H, ArH), 
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7.35 (d, J = 7.6 Hz, 1H, ArH), 7.27 (d, J = 6.6 Hz, 1H, ArH), 7.22 (s, 1H, ArH), 
7.17 (t, J = 7.3 Hz, 1H, ArH), 6.84 (s, 4H, ArH), 4.23 (ddd, J = 16.5, 10.7, 5.5 
Hz, 13H, OCH2), 3.88 (dd, J = 9.6, 4.3 Hz, 7H, OCH2), 3.86 – 3.79 (m, 6H, 
OCH2), 3.73 (dd, J = 7.7, 4.9 Hz, 13H, OCH2), 3.69 – 3.60 (m, 27H, OCH2), 
3.54 (ddd, J = 13.3, 6.8, 3.7 Hz, 13H, OCH2), 3.37 (dd, J = 10.4, 2.6 Hz, 18H, 
OCH3), 1.62 (s, 2H, CH3), 1.48 (s, 4H, CH3). 
13
C NMR (100 MHz, CDCl3): C 
153.58, 152.88, 152.56, 150.25, 149.02, 147.69, 147.52, 140.96, 140.63, 
134.30, 131.96, 130.91, 128.69, 127.25, 126.07, 125.32, 122.48, 121.50, 
121.09, 119.29, 116.36, 111.22, 107.84, 72.51, 71.93, 70.62, 69.70, 69.07, 
58.97, 13.73, 13.57 ppm.  
 
2.2.9. Synthesis of Compound 38 
 
 
Figure 28. Synthesis of Compound 38 
Compound 34 (0.176 mmol, 60 mg) is dissolved in 20 mL mixture 
(DMF/DCM, 1:1, v/v). Then, N-Bromosuccinimide (0.37 mmol, 66mg) is 
dissolved in DCM (10 mL) and added dropwise to reaction mixture. The 
mixture is stirred at room temperature. The reaction is monitored by TLC. After 
finishing starting material 5-10 minutes were waited, reaction is stopped by 
adding 100 mL of water. The mixture is extracted into DCM (3x 100 mL). The 
organic phase was dried over Na2SO4 and concentrated in vacuo. Then crude 
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product was purified by silica gel column chromatography (Acetone/ Hexane, 
1:4, v/v). Red solid was obtained (0.031 g, 35%). 
1
H NMR (400 MHz, CDCl3): 
H 7.54 (dt, J = 8.7, 2.3 Hz, 1H, ArH), 7.27 (d, J = 2.8 Hz, 1H, ArH), 6.96 (d, J 
= 8.7 Hz, 1H, ArH), 5.68 (d, J = 5.5 Hz, 1H, OH), 2.54 (s, 6H, CH3), 1.59 (s, 
6H, CH3). 
13
C NMR (100 MHz, CDCl3): C 155.07, 151.75, 140.46, 134.43, 
131.51, 122.50, 118.75, 113.58, 112.29, 29.69, 13.65, 13.29 ppm. MS (TOF- 
ESI): m/z: Calcd for C19H16BBr3F2N2O: 572.8874 [M-H]
- 
, Found: 572.8837 
[M-H]
-
 , Δ=6.45 ppm. 
 
2.2.10. Synthesis of Compound 39 
 
 
Figure 29. Synthesis of Compound 39 
Compound 38 (0.348 mmol, 200 mg) and 3,4,5-tris(2-(2-(2-
methoxyethoxy)ethoxy)ethoxy) benzaldehyde (0.731 mmol, 433 mg) were 
added into a 100 mL round-bottomed flask equipped with a Dean-Stark 
apparatus. 40 mL of benzene, acetic acid (0.2 mL) and piperidine (0.2 mL) 
were added and mixture was stirred at reflux temperature. The reaction was 
monitored by TLC and continued until starting material was finished. Water 
(100 mL) was added to reaction mixture which was cooled to room 
temperature. Mixture was extracted into DCM (3x 100 mL). The organic phase 
was dried over Na2SO4 and concentrated in vacuo. The crude product was 
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purified by silica gel column chromatography (DCM/ MeOH, 95:5, v/v). The 
product was collected as green solid (240 mg, 40 %). 
1
H NMR (400 MHz, 
CDCl3): H 7.97 (d, J = 16.5 Hz, 2H, CH), 7.44 (dd, J = 9.1, 2.3 Hz, 1H, ArH), 
7.30 (d, J = 14.4 Hz, 2H), 7.13 (d, J = 2.6 Hz, 1H, ArH), 6.96 (d, J = 8.8 Hz, 
1H, ArH), 6.88 (s, 4H, ArH), 4.26 (d, J = 2.7 Hz, 8H, OCH2), 4.21 – 4.17 (m, 
4H, OCH2), 3.89 (t, J = 4.8 Hz, 9H, OCH2), 3.81 (dd, J = 5.8, 4.2 Hz, 4H, 
OCH2), 3.76 – 3.70 (m, 14H, OCH2), 3.68 – 3.60 (m, 27H, OCH2), 3.58 – 3.54 
(m, 6H, OCH2), 3.54 – 3.50 (m, 7H, OCH2), 3.38 (s, 8H, OCH3), 3.35 (s, 10H, 
OCH2), 1.28 (s, 6H, CH3). 
13
C NMR (100 MHz, CDCl3): C 152.74 , 152.59 , 
148.25 , 141.02 , 140.37 , 139.50 , 134.35 , 132.45 , 131.98 , 131.54 , 122.80 , 
118.93 , 116.42 , 112.75 , 110.72 , 107.92 , 77.39 , 77.07 , 76.75 , 72.47 , 71.92 
, 70.82 , 70.67 , 70.52 , 69.70 , 69.07 , 58.97 , 13.12 ppm. MS (TOF- ESI): m/z: 
Calcd for C75H108BBr3F2N2O25: 1720.4852 [M-H]
-
, Found: 1720.4714 [M-H]
-
 , 
Δ=8.02 ppm.  
 
2.2.11. Synthesis of Compound 40 
 
 
Figure 30. Synthesis of Compound 40 
Compound 39 (0.24 mmol, 400 mg) was dissolved in dry THF (30 mL). 
Then triethylamine (0.12 mL) was added and stirred for 30 min at room 
temperature. A solution of 2, 4-dinitrobenzenesulfonyl chloride (0.77 mmol, 
200 mg) in dry THF (20 mL) was added dropwise at 0 ◦C. The mixture was 
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heated to 40 ◦C and stirred for overnight. Then reaction was cooled to room 
temperature and solvent was evaporated. Crude product was purified by silica 
gel column chromatography (DCM/ MeOH, 95:5, v/v). The product was 
collected as pale green solid (274 mg, 60 %). 
1
H NMR (400 MHz, CDCl3): H 
8.61 (s, 1H, ArH), 8.26 (dd, J = 8.6, 2.5 Hz, 1H, ArH), 7.96 (d, J = 16.4 Hz, 2H, 
CH), 7.83 (dd, J = 8.9, 2.6 Hz, 1H, ArH), 7.78 (d, J = 8.9 Hz, 1H, ArH), 7.57 – 
7.49 (m, 2H, ArH), 7.24 (d, J = 16.5 Hz, 2H, CH), 6.85 (s, 4H, ArH), 4.30 – 
4.17 (m, 13H, OCH2), 3.90 (t, J = 6.3 Hz, 9H, OCH2), 3.84 (t, J = 10 Hz, 5H, 
OCH2), 3.76 – 3.73 (m, 13H, OCH2), 3.70 – 3.63 (m, 28H, OCH2), 3.57 (dd, J = 
4.0, 2.1 Hz, 4H, OCH2), 3.54 (dd, J = 5.8, 3.8 Hz, 8H, OCH2), 3.39 (s, 6H, 
OCH3), 3.37 (s, 12H, OCH3), 1.57 (s, 6H, CH3). 
13
C NMR (100 MHz, CDCl3): 
C 213.36, 152.94, 150.37, 149.35, 147.71, 146.64, 141.34, 140.80, 140.32, 
134.91, 134.03, 133.70, 131.87, 131.75, 130.97, 129.24, 126.82, 126.11, 
121.97, 121.63, 116.27, 107.96, 72.55, 71.95, 70.68, 70.60, 70.55, 69.72, 69.10, 
59.00, 58.98, 13.86.  
 
 
 
 
 
 
 
 
 
 
 
45 
 
CHAPTER 3 
 
RESULTS & DISCUSSION 
 
 
3.1. General Perspective  
 
Several difficulties have been got over in order to improve the ideal 
photosensitizers for PDT. Scientist aimed high phototoxicity and selectivity for 
tumor tissues, at the same time decreased side effects caused by the method. 
High absorption coefficients and quantum yields for singlet oxygen generation 
are the a few features for good photosensitizers. Another important 
characteristic for photosensitizers is biocompatibility since the method for 
biological applications. Due to the results obtained from clinical trials, it is a 
fact that side effects need to diminish. Although second generation 
photosensitizers have been designed for this need, they couldn’t present 
sufficient selectivity hence the results
131,11
. Through designing activatable water 
soluble photosensitizers, sensitivity and selectivity of the method are 
enhancing.  
In this study, we have reported three different Bodipy based 
photosensitizers in order to compare the importance of proximity of 2,4 – 
dinitrobenzenesulfonyl group. All of them are water soluble through 
conjugating triethylene glycol derivatives. The main purpose for the design is to 
increase selectivity of the PDT through activation of the photosensitizers by 
glutathione which is overexpressed in cancer tissues up to 50 folds
101,102
. 
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3.2. Design Strategies for Activatable Photosensitizers 
 
 
Figure 31. Targeted Probe Design 
The reason for use Bodipy dyes for PDT action is their exceptional 
chemical and photophysical properties. This class of dye has high extinction 
coefficient in visible and near-IR region around 70 000 – 100 000 M-1 cm-1. 
Ease of purification and straight forward synthesis are important parameters 
that enable us modify the dye according to needs for methods. Through 
adjustments, absorption maxima of Bodipy could shift to longer wavelengths 
which are in therapeutic window range. Increasing intersystem crossing via 
heavy atom effect let energy transfer rate also enhances due to longer excited 
state lifetimes. Due to this rise, singlet oxygen generation efficiency has been 
improved which enable phototoxicity of the method has been accomplished
59
. 
Other functional groups could be located over Bodipy core with different type 
of reactions. In Fig. 31, compound 37 is an example for different variation that 
leads target photosensitizers. Triethylene glycol groups are used for water 
solubility for biological applications. 2, 4 dinitrobenzenesulfonyl group is 
purposed for GSH sensing.  
37 
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Figure 32. Target Photosensitizers 
Meso position of the Bodipy which is also called position 8 could be 
designed with suitable aldehydes for the purpose. Other positions like 1,3,5 and 
7 could be modified via Knoevenagel condensation reaction. In these designs, 
only 3 and 5 positions are used for water solubility design through manipulating 
triethylene glycol derivatives. Condensation reactions could occur due to the 
acidic nature of the methyl groups in the positions previously mentioned. 
Electrophilic bromination is favorable via 2 and 6 positions. In the last step, SN2 
take place in order to modification of the 2,4 dinitrobenzenesulfonyl chloride to 
Bodipy core. By means of these reactions, effective photosensitizers are 
designed for PDT action as in designs in Fig.32
59
.  
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Figure 33. Activation of the Photosensitizers 
Fluorescence of the probe is quenched through donor-excited 
photoinduced electron transfer (d-PeT) from Bodipy to 2, 4 dinitrobenzene- 
sulfonyl group. After addition of the glutathione (GSH), fluorescence returns. 
In this design, almost no fluorescence is observed until addition of the GSH. 
Visible light is used in order to excite the probe. 2, 4 dinitrobenzenesulfonyl 
groups act as electron acceptor in the PeT process. In order to tackle certain 
limitations, our design is highly selective towards glutathione via d-PeT 
process. In order to understand para and ortho position’s importance, different 
designs are used in the research to compare the results. One of the reasons of 
these designs is to prove that distance between electron acceptor and electron 
donor is very significant factor which affect the quenching process. In Fig. 33, 
illustration of the quenching of the fluorescence and restoring it is available 
through using compound 37 as an example. Depending on quenching and 
restore of the PeT mechanism, this process called off-on procedure. Off state is 
called probe and on state is called Bodipy through the measurements. 
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3.3 Spectral Proof for Activation Process 
 
Figure 34. Absorbance spectrum of Compound 32 and Compound 33 as 
Bodipy 1 and Probe 1 respectively before and after addition of GSH. 
 
 
 
Figure 35. Fluorescence spectrum of Compound 33 as Probe 1 with time, 1 nM 
GSH and 4 µM Probe concentration in DMSO/ 1X PBS buffer solution (1/1, 
v/v), excitation wavelength was 655 nm 
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Least reactive targeted photosensitizers is compound 33 in which para 
position is substituted with electron acceptor 2,4 dinitrobenzenesulfonyl group. 
In Fig.34 and Fig. 35 , absorbance and fluorescence spectra are presented. 
Through absorbance spectrum, there is 98 nm difference between compound 32 
(Bodipy 1) and compound 33 (Probe 1). Fluorescence spectrum is the proof for 
the off- on state thiol sensitive photosensitizer. Upon the addition of the GSH , 
7.3 folds increase observed in spectrum. Measurements were taken until no 
change was observed in the fluorescence. It took 270 minutes to complete the 
measurement for this case.  
 
 
 
Figure 36. Absorbance spectrum of Compound 36 and Compound 37 as 
Bodipy 2 and Probe 2 respectively before and after addition of GSH. 
 
In Fig. 36 , UV-Vis absorbance spectrum is presented for compound 36 
and 37 before and after GSH addition. Reactions toward GSH are so fast that it 
took only half an hour to measure the changes. Upon addition of GSH, Probe 
2’s spectrum transforms to Bodipy 2’s spectrum showing the transformation  
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Figure 37. Fluorescence spectrum of Compound 37 as Probe 2 with time, 1 nM 
GSH and 4 µM Probe concentration in DMSO/ 1X PBS buffer solution (1/1, 
v/v), excitation wavelength was 655 nm 
 
since it could be seen through spectrum. Another proof for the transformation is 
fluorescence spectrum for compound 37 as Probe 2. Upon addition of the GSH, 
restoration of the fluorescence is took place. No change has been observed after 
90 minutes for fluorescence measurements in this case.  
Last but not least Probe 3 is the most reactive towards to GSH. In Fig. 38 
and 39 absorbance and fluorescence spectra are presented respectively. Half an 
hour is sufficient for the measurements process in order to observe change for 
this compound, Probe 2. Upon addition of the GSH, fluorescence restored in 30 
minutes which is the fastest response when compared to other Probes for GSH 
response in this study. Since activation process could be achieved without 
difficulties, only singlet oxygen generation factor is needed for understand the 
PDT power of these study. 
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Figure 38. Absorbance spectrum of Compound 39 and Compound 40 as 
Bodipy 2 and Probe 2 respectively before and after addition of GSH. 
 
Figure 39. Fluorescence spectrum of Compound 40 as Probe 2 with time, 1 nM 
GSH and 4 µM Probe concentration in DMSO/ 1X PBS buffer solution (1/1, 
v/v), excitation wavelength was 655 nm 
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3.4 Singlet Oxygen Generation 
 
 
Figure 40. Absorbance spectrum of trap molecule (2,2'-(Anthracene-9,10-
diyl)bis(methylene)dimalonic acid) with Bodipy 1, 4 µM in DMSO/ 1X PBS 
buffer solution (1/1, v/v), LED applied at 660 nm. 
 
Trough using trap molecules, singlet oxygen measurements are done. 
Difficulties of direct measurements of singlet oxygen molecules arouse because 
of the short life time of these molecules. Trap molecules is reacting with singlet 
oxygen molecules hence the absorption of trap molecules is decreasing depend 
on the singlet oxygen amount directly. Measurements are taken in the dark in 
order to show that there is not any singlet oxygen generation in the dark. Then 
light is applied at 660 nm to produce reactive oxygen species. As you can see 
all of the tree spectra show excellent singlet oxygen efficiency. 
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Figure 41. Absorbance spectrum of trap molecule (2,2'-(Anthracene-9,10-
diyl)bis(methylene)dimalonic acid) with Bodipy 2, 4 µM in DMSO/ 1X PBS 
buffer solution (1/1, v/v), LED applied at 660 nm 
 
Figure 42. Absorbance spectrum of trap molecule (2,2'-(Anthracene-9,10-
diyl)bis(methylene)dimalonic acid) with Bodipy 3, 4 µM in DMSO/ 1X PBS 
buffer solution (1/1, v/v), LED applied at 660 nm 
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CHAPTER 4 
 
CONCLUSION 
 
 
 In this study, we have synthesized three different photosensitizers for 
activatable PDT action. This study has been demonstrated the importance of the 
ortho and para positions for activation process of the photosensitizers for PDT 
action. Process properties are emphasized through the photophysical changes in 
spectrum which confirm the logic behind the design. 
This is especially important for cancerous diseases. Energy transfer 
systems are also used for various purposes as imaging of live cell protein 
localizations, monitoring of drug release. Demand for cure, new treatment 
modalities for cancer has increasing trends in materials science, biology and 
chemistry. Significant importance of these systems and contributions to the 
science cannot be underestimated. Since photodynamic therapy is one of the 
most informative and sensitive method, applications in research will continue to 
increase. Through the different remarkable processes, it will be more lucid to 
see the important assistance of these systems.  
We will continue with in vitro experiments for our activatable 
photosensitizers in order to observe the PDT effect in tumor cells. Upon the our 
results, new photosensitizers could be designed for literature or clinical trials 
could be planned.  
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Appendix A 
NMR Spectrum 
 
Figure 43. 
1
H NMR spectra of compound 30 
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Figure 44. 
13
C NMR spectra of compound 30 
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Figure  45. 
1
H NMR spectra of compound 31 
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Figure 46. 
13
C NMR spectra of compound 31 
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Figure 47. 
1
H NMR spectra of compound 32 
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Figure 48. 
13
C NMR spectra of compound 32 
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Figure 49. 
1
H NMR spectra of compound 33 
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Figure 50. 
13
C NMR spectra of compound 33 
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Figure 51. 
1 
H NMR spectra of compound 34 
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Figure 52. 
13 
C NMR spectra of compound 34 
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Figure 53. 
1 
H NMR spectra of compound 35 
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Figure 54. 
13 
C NMR spectra of compound 35 
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Figure 55. 
1 
H NMR spectra of compound 36 
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Figure 56. 
13 
C NMR spectra of compound 36 
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Figure 57. 
1 
H NMR spectra of compound 37 
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Figure 58. 
13 
C NMR spectra of compound 37 
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Figure 59. 
1 
H NMR spectra of compound 38 
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Figure 60. 
13 
C NMR spectra of compound 38 
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Figure 61. 
1 
H NMR spectra of compound 39 
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Figure 62. 
13 
C NMR spectra of compound 39 
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Figure 63. 
1 
H NMR spectra of compound 40 
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Figure 64. 
13 
C NMR spectra of compound 40 
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APPENDIX B 
 
MASS SPECTRA 
 
 
Figure 65. ESI-HRMS of compound 30 
 
 
 
 
Figure 66. ESI-HRMS of compound 31 
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Figure 67. ESI-HRMS of compound 32 
 
 
Figure 68. ESI-HRMS of compound 34 
 
 
Figure 69. ESI-HRMS of compound 35 
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Figure 70. ESI-HRMS of compound 36 
 
 
Figure 71. ESI-HRMS of compound 38 
 
 
Figure 72. ESI-HRMS of compound 39 
 
